Abstracts

Abstract submission

Submission status:
Open

Abstract Submission deadline extended:
9 october 2024

Abstract notification:
18 October 2024

Abstract submission for ISRA 2024 is extended and open until 9 october, 23:59 CET. 

All presenters will be required to attend in-person to make their Oral or Poster Presentations.

  • Abstracts for the ISRA2024 Symposium must be submitted online via the abstract submission site. Emails and word processing files submitted outside the abstract submission site will not be accepted.
  • There is no limit to the number of abstracts an author may submit; however, an author may only serve as the presenting author on two submissions.
  • It is the author’s responsibility to designate a new presenter for presentation conflicts that arise.
  • If accepted, the presenter must be an author, or a co-author listed on the abstract at the time of submission.
  • Abstracts must have a complete status by the abstract deadline, or the abstract will not be considered for the ISRA2024 program. Extensions will not be granted.

Abstracts are limited to 200 words (excluding references). Please use the Vancouver style for all references. If necessary, the methods section should contain the sex and number of animals or humans included in the study, together with ethical approval information.

The abstract submitter needs to select a primary and a secondary category in which their abstract will be considered.

  • Abstracts must be written in English.
  • Do not enter author information into the abstract body. Author affiliations will be added automatically based on the information entered during the submission process.
  • Do not include the abstract title or grant support in the abstract body.
  • Standard abbreviations may be used without definition. Nonstandard abbreviations must be placed in parentheses after the first use of the abbreviation.
  • When submitting your abstract, the ISRA2024 Abstract Scientific Committee recommends using language that is neutral, nonjudgmental, and free from stigma.
  • Proofread abstracts carefully to avoid errors. Modifications will not be allowed after the October 9, 2024, deadline.
  • Note: The Abstract Scientific Committee may modify the format to fit the look and feel of the media on which it is displayed or distributed.

All abstracts successfully submitted are reviewed by the ISRA2024 Abstract Scientific Committee.

Originality of work, adequacy of data, and clarity of exposition are the determinants in the selection of abstracts. An abstract that does not present the results of the study will not be considered for oral communication but may be eligible for a poster presentation.

The final decision with respect to the selection and programming of any abstract will be made by the ISRA2024 Abstract Scientific Committee.

Abstracts may be selected for oral presentation or poster presentation, or not selected.

Abstract acceptance status will be sent via email to the designated presenting author on October 18.

  • Submission of an abstract grants ISRA2024 the right to publish the abstract in The Journal of Vascular Research and on the symposium website isra2024.org.
  • Abstracts may be revised online until October 9. Modifications will not be allowed after the submission deadline.

Abstract presenters will be required to attend ISRA2024 in-person to make their presentation. Expenses associated with an abstract presentation (e.g., travel, hotel, congress registration fees, etc.) are the sole responsibility of the presenting author.

Presenters must register for the symposium before the abstract submission deadline of October 9 to be considered for presentation at the symposium. Abstracts that are not accompanied by an author registration will not be part of the abstract review & selection.

Contact: For questions regarding abstract submission, contact the ISRA2024 Symposium Secretariat at info@cap-partner.eu

Submission status:
Open

Abstract Submission deadline, extended:
9 october 2024

Abstract notification:
18 October 2024